Schizophrenia is frequently a chronic and disabling disorder, characterized by
heterogeneous positive and negative symptom constellations. The objective of this review …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …

Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

In situ forming implants, defined as liquid formulations that generate solid or semisolid
depots following administration, have shown a range of advantages in drug delivery. This …

Autism spectrum disorders (ASD) are a group of disorders characterized by impairment in
social communication and repetitive and stereotyped behaviors. ASD etiology is very …

The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal
transduction system, are long-established as attractive therapeutic targets. During …

Negative symptoms of schizophrenia are debilitating and chronic in nature, are difficult to
treat, and contribute to poor functional outcomes. Motivational deficits are a core negative …

KarXT combines xanomeline, an M1/M4 preferring muscarinic agonist with no direct D2
receptor antagonism, with the peripherally restricted anticholinergic trospium. In …

The causal mechanisms and treatment for the negative symptoms and cognitive dysfunction
in schizophrenia are the main issues attracting the attention of psychiatrists over the last …